Reuters |
AstraZeneca boosted by good results for biotech asthma drug
Reuters LONDON AstraZeneca's (AZN.L) drive to rebuild its portfolio of new medicines received a boost on Tuesday with positive results for a biotech drug for severe asthma that the company has previously flagged as a potential $2 billion-a-year product. AstraZeneca: Asthma drug trial results positive Astrazeneca Reports Results On Benralizumab Phase III Programme In Severe Asthma TOP NEWS: AstraZeneca Gets Positive Benralizumab Phase III Trial Results |
View full post on asthma – Google News